Subject: Re: Rankings for 26Aug2024
VRTX had a very large expense charge related to is recent purchase.

From an Aug 1 press release.

In May, Vertex completed its previously announced acquisition of Alpine Immune Sciences for approximately $5.0 billion in cash, including Alpine’s lead asset povetacicept, resulting in an approximate $4.4 billion charge to AIPR&D expenses in the second quarter of 2024.

https://investors.vrtx.com/new...